Leading Melanoma Specialist Validates Ablative Ability And Systemic Effects Of Provectus Pharmaceuticals Inc. Anti-Cancer Agent PV-10

KNOXVILLE, Tenn., Sept. 14 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT - News) announced today that Professor Peter Hersey, M.D., presented results at the Third Annual International Melanoma Research Congress, September 14-16, 2006, in Noordwijk, The Netherlands that outlined how the Company's leading anti-cancer agent, PV-10, completely ablated a cluster of metastatic melanoma tumors afflicting a clinical trial participant. Hersey, an oncologist and leading international authority on melanoma, noted that treatment of one of the tumors with PV-10 led to complete eradication of all four tumors that had repeatedly resisted treatment with surgery, chemotherapy and radiation therapy.

Back to news